NDAORALTABLETPriority Review
Approved
Apr 1977
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
4/8 — Partial
Priority Review
LODOSYN (carbidopa tablets) by Atonco is dopa decarboxylase inhibitors [moa]. Approved for aromatic amino acid decarboxylation inhibitor [epc]. First approved in 1977.
Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LODOSYN (carbidopa) is an oral DOPA decarboxylase inhibitor approved in 1977 for use as an adjunct in Parkinson's disease treatment. It works by inhibiting the conversion of levodopa to dopamine in the periphery, allowing more levodopa to reach the brain. This mechanism enables lower levodopa doses and reduces peripheral dopamine side effects.
LOE Approaching
With LOE approaching and competitive pressure at 30%, the brand team is likely in maintenance mode with limited expansion opportunities and stable headcount.
Mechanism of Action
DOPA Decarboxylase Inhibitors
Pharmacologic Class:
Aromatic Amino Acid Decarboxylation Inhibitor
Indications (1)
Career Relevance
Working on LODOSYN offers limited upside career trajectory; the product is in maintenance mode with minimal growth potential as it approaches loss of exclusivity. Career value lies in mastering niche neurology expertise, lifecycle management, and cost-containment strategy in a mature branded generic market.
Worked on LODOSYN at Atonco? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.